CMR Reclassification: Is Your EU & UK CPSR Still Compliant?

TABLE OF CONTENTS

• How CMR Reclassification Can Change Your Cosmetic Safety Assessment in the EU and UK
• What Are CMR Substances?
• The Three Categories
• What Is CMR Reclassification, And Why Does It Happen?
• Classification vs Reclassification:
• The Legal Rules, Article 15 of the EU Cosmetics Regulation
• What Goes Into Annex II
• How Reclassification Directly Impacts Your CPSR
• Reclassification Scenarios
• Trace Impurity Limitations: The Details Most Assessors Miss
• What Article 15 say
• What a Strong CPSR Looks Like for CMR Compliance
• Key 2026 Regulatory Updates: EU and UK
• EU vs UK Post-Brexit
• What to Do When Reclassification Hits Your Formula
• FAQs
• What is Article 15 of the EU Cosmetics Regulation?
• What is the cosmetic safety assessment in Europe?
• What is Article 19 of the EU Cosmetics Regulation?
• What are the classification categories of CMR substances?

How CMR Reclassification Can Change Your Cosmetic Safety Assessment in the EU and UK

You didn’t change your formula, but your product is suddenly non-compliant. That’s the reality of CMR reclassification in cosmetics.

Under EU Regulation (EC) No 1223/2009 and updates from the European Chemicals Agency, ingredients can be reclassified as carcinogenic, mutagenic, or toxic for reproduction (CMR) based on new scientific evidence. When this happens, substances may be added to Annex II (banned ingredients list), instantly impacting your Cosmetic Product Safety Report (CPSR) and overall cosmetic compliance in the EU and UK.

In many cases, brands receive no direct warning. A previously approved ingredient can become restricted or prohibited, making your product illegal on the market overnight.

This guide explains:

What CMR substances are in cosmetics?

How does reclassification work under CLP Regulation?

How does it affect your cosmetic safety assessment (CPSR)?

And what the 2026 regulatory updates mean for your business

If you sell cosmetics in the EU or UK, understanding CMR reclassification is essential to keep your products compliant and market-ready.

What Are CMR Substances in Cosmetics?

CMR substances are chemicals classified as carcinogenic, mutagenic, or toxic for reproduction.

These aren't just warning labels on a safety data sheet. In cosmetics, CMR status determines whether an ingredient is even legal to use. That's why understanding this is so important for anyone doing a cosmetic safety assessment.

The Three Categories

There are three CMR categories. Each one reflects how strong the evidence is against a substance.

CMR 1A means the hazard is proven in humans. Real data, real people. CMR 1B means it's presumed; strong animal evidence points to the same conclusion. And CMR 2 means it's suspected, early or limited data raises concern, but nothing definitive yet.

1A and 1B are treated almost identically under EU law. Category 2 is where things get more complex. We'll get to that.

What Is CMR Reclassification, And Why Does It Happen?

Classification is a starting point. Reclassification happens when the original classification changes over time.

A substance gets reclassified when new evidence changes how regulators see its risk. That could be a long-term study that wasn't available before. It could be a meta-analysis that pulls together years of animal data. Sometimes it's political, such as increased regulatory scrutiny on a whole class of chemicals. The reasons may vary. But the outcome is the same: the number next to that ingredient in your formula changes.

And reclassification goes both ways. A substance can move up, from CMR 2 to CMR 1B, for example, which is a significant jump. Or it can move down, declassified entirely if new evidence shows earlier concerns were overstated. Both directions matter for your CPSR assessment.

Some of the examples are; Photoinitiators, used in UV-cured coatings and some packaging processes, have been moving into CMR 2 territory based on reproductive toxicity data. Organotin compounds, used historically as stabilisers, have had several members reclassified into CMR 1B. These aren't obscure chemicals. They show up in supply chains more than people expect.

Classification vs Reclassification:

The Legal Rules, Article 15 of the EU Cosmetics Regulation

This is the legal core of everything we've discussed. Article 15 of the EU Cosmetics Regulation (EC) No 1223/2009 is where the rules are written.

CMR 1A and 1B substances are prohibited in cosmetic products.  For example,  a preservative used in your formula gets reclassified as CMR 1B.

Result:

• The product becomes illegal in the EU
• Reformulation required
•  CPSR must be rewritten

CMR 2 substances are also prohibited by default. But, and this is important, there's a derogation path.

A CMR 2 substance can be permitted if three conditions are all met at the same time. First, the Scientific Committee on Consumer Safety (SCCS) must evaluate the substance and confirm it's safe for use in cosmetics. Second, there must be no suitable safer alternatives available. Third, the use must be limited to a specific, defined application. All three. Not two out of three.

This isn't a loophole, it's a narrow, science-backed exception. And it only applies to Category 2.

What Goes Into Annex II

Annex II is basically the cosmetics banned list. When a substance gets classified or reclassified as CMR 1A or 1B, the European Commission adds it to Annex II. Your formula can no longer legally contain it.

The important thing to understand is that Annex II updates follow CLP changes. There's a lag, sometimes months. But the direction is one-way. Once something lands on Annex II, it stays until the science changes dramatically.

How Reclassification Directly Impacts Your CPSR

Your cosmetic safety report was accurate when it was written. But if an ingredient gets reclassified after sign-off, that document can become non-compliant, without you touching anything.

A compliance document  is a living document. And CMR reclassification is one of the main reasons it needs to be monitored, not just filed.

When reclassification hits, your assessor needs to act across three areas:

Substance Confirmation

• Confirm whether your formula contains the affected substance
• Check for presence even as a trace impurity, not just as a listed ingredient

Derogation Review

• Determine whether a derogation exists for the reclassified substance
• Assess whether that derogation applies to your specific product and use case

Document Decision

• Decide whether the existing CPSR can be amended to reflect the change
• Or determine whether the report needs to be fully reissued from scratch

Reclassification Scenarios

Different reclassification directions mean different outcomes for your CPSR cosmetics documentation.

Trace Impurity Limitations: The Details Most Assessors Miss

What if the CMR substance isn't an intentional ingredient, just a contaminant, by-product, or residue in a raw material?

Why this is more common than brands realise

• Raw materials aren't perfectly pure
• Processing leaves residues
• Natural extracts carry trace compounds
• Some of those trace compounds carry CMR classifications

This means your formula could contain a CMR substance that nobody put there on purpose.

What Article 15 says

• There is a specific provision for technically unavoidable trace amounts of CMR 1A or 1B substances
• If the presence is genuinely unavoidable with current technology, and the concentration poses no realistic risk, the product can still be considered safe
• "Trace" is not a magic word; you cannot just say it and move on

What a Strong CPSR Looks Like for CMR Compliance

Not all safety assessors approach CMR ingredients the same way, and that gap in quality is where real risk sits.

A strong CPSR doesn’t just tick boxes. It goes deeper. It looks at the full toxicological profile of every ingredient, verifies current classifications, and flags substances that are under review,  not just the ones already restricted. That’s the difference between a report that passes and one that actually protects your brand.

Here’s what a compliant, high-quality CPSR should clearly include:

• Up-to-Date CMR Classification (CLP Annex VI Check)
   Every ingredient must be verified against the current CLP Annex VI,  not an outdated version.
   The report should also show when this check was last done, not just when the CPSR was signed.

• Forward Risk Awareness (Not Just Current Status)
   Substances under active regulatory review should be flagged early.
   Waiting for official reclassification is risky; strong assessors treat this as an early warning system.

• Article 15 Compliance Statement
   A clear statement confirming compliance with Article 15 is essential.
   This is the legal backbone for handling CMR substances in cosmetic products.

• CMR 2 Ingredient Justification (If Applicable)
   If any CMR 2 substances are present, the report must confirm whether a derogation applies.
   It should also explain the legal and scientific basis for that decision.

• Trace Impurity Analysis (With Real Data)
   This is where many reports fall short. Trace impurities must be addressed with actual, measurable data, not assumptions.

• Supplier Specifications (Verified Data)
   Confirm exact impurity levels in each raw material
   Include certificates or technical data sheets
   Ensure values are measurable, not estimated

• Toxicological Threshold (Defined Safety Limit)
   State the safe limit for the substance
   Reference to who established this limit
   Base it on recognised toxicological data

• Safety Justification (Evidence-Based Conclusion)
   Link the measured level to the safety threshold
   Clearly explain why it does not pose a risk
   Provide a logical, data-backed conclusion

“Present at trace levels, considered safe” is not a safety justification. It sounds convincing, but without supporting data, it leaves your brand exposed.

If your current CPSR is missing any of the above, it’s worth a proper review,  especially with 2026 regulatory updates tightening expectations across multiple ingredient categories.

Key 2026 Regulatory Updates: EU and UK

The regulatory picture has shifted. And if your CPSR assessment hasn't been reviewed recently, there are specific 2026 developments worth knowing about.

EU vs UK Post-Brexit

The UK now runs its own system, and it diverges from the EU. That's not just a technicality. It's a real compliance risk for dual-market brands.

The UK Cosmetics Regulation (retained EU law, updated independently) is managed through the Office for Product Safety and Standards (OPSS). UK CLP classifications are handled by the Health and Safety Executive (HSE). These bodies don't automatically mirror EU decisions. A substance reclassified by ECHA might not appear in UK Annex II for months, or it might be handled differently altogether.

If you're selling in both markets, and many brands are, your cosmetic safety assessment needs to account for both systems separately. One CPSR covering both isn't always enough anymore.

What to Do When Reclassification Hits Your Formula

So it happened. A substance in your formula just got reclassified. Here's the practical process, step by step.

Step 1: Identify what's affected. The moment a new ATP round is published, cross-reference your full ingredient list, including raw material components and known impurities, against the updated CLP Annex VI. This sounds tedious. It is. But it's the only way to catch issues before they become problems.

Step 2: Contact your safety assessor immediately. Don't wait for your scheduled review. Reclassification is a trigger event. Your assessor needs to evaluate whether your existing CPSR cosmetics documentation is still valid, whether a derogation applies, and what the timeline looks like for any required changes.

Step 3: Reformulate if necessary. If the substance is now CMR 1A or 1B, and no derogation exists, you reformulate. There's no workaround. Find a compliant alternative, and document why you chose it.

Step 4: Rerun the safety assessment. A new formula needs a new cosmetic product safety assessment. Your assessor evaluates the replacement ingredient under the same full toxicological process. Don't skip this; using a new ingredient without assessment is its own compliance issue.

Step 5: Update your market notifications. EU products are notified through the Cosmetic Products Notification Portal (CPNP). UK products go through the UK Responsible Person notification system. Formula changes require updated notifications in both.

FAQs

What is Article 15 of the EU Cosmetics Regulation?

Article 15 is the provision in EC No 1223/2009 that governs CMR substances in cosmetics. It prohibits CMR 1A and 1B substances outright; they're listed in Annex II as banned ingredients. CMR 2 substances are also prohibited by default, but can be permitted through a derogation process if the SCCS confirms safety, no alternatives exist, and use is limited to a specific application.

What is the cosmetic safety assessment in Europe?

A cosmetic safety assessment, documented in the CPSR (Cosmetic Product Safety Report), is a mandatory evaluation required before any cosmetic product is placed on the EU market. It must be completed by a qualified safety assessor. It covers toxicological profiles of all ingredients, CMR status, formula stability, microbiological safety, and claims substantiation.

What is Article 19 of the EU Cosmetics Regulation?

Article 19 covers labelling requirements for cosmetic products sold in the EU. This includes the full ingredient list (INCI names), the responsible person's details, product function, and any required warnings. It's a separate obligation from the safety assessment requirements under Article 10 and Article 15, but equally important for market compliance.

What are the classification categories of CMR substances?

CMR substances are classified under the EU CLP Regulation into three categories. CMR 1A, proven human hazard, based on human epidemiological data. CMR 1B, presumed human hazard, based on strong animal evidence. CMR 2, suspected hazard, based on limited or preliminary data.

In cosmetics, 1A and 1B are banned outright. CMR 2 substances are banned by default but may be permitted through a specific SCCS-backed derogation process.